2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
10163
Neoplasms
7801
Carcinoma, Non-Small-Cell Lung
5744
Prostatic Neoplasms
5016
Colorectal Neoplasms
4588
Lung Neoplasms
3716
Leukemia, Myeloid, Acute
3097
Neoplasm Metastasis
3074
Multiple Myeloma
3073
Pancreatic Neoplasms
2837
Melanoma
2646
Lymphoma
2569
Ovarian Neoplasms
2565
Carcinoma, Hepatocellular
2473
Stomach Neoplasms
2325
Recurrence
2221
Head and Neck Neoplasms
2095
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2084
Lymphoma, Non-Hodgkin
2055
Leukemia
2011
Brain Neoplasms
1899
Glioblastoma
1791
Colonic Neoplasms
1790
Leukemia, Lymphocytic, Chronic, B-Cell
1771
Rectal Neoplasms
1714
Uterine Cervical Neoplasms
1684
Lymphoma, Follicular
1651
Squamous Cell Carcinoma of Head and Neck
1649
Lymphoma, Large B-Cell, Diffuse
1596
Carcinoma, Renal Cell
1574
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts